Erasca

Erasca FCF/Debt

The Free Cash Flow to Debt Ratio of Erasca (ERAS) as of Oct 23, 2026 is -169.35 %. In the previous year, Free Cash Flow to Debt Ratio was -175.73 % — a change of -3.63% (higher).

FCF/Debt

-169.35 %

YoY

-3.63%

Last updated:

Free Cash Flow to Debt Ratio of Erasca is 2025 -169.35 % . Free Cash Flow to Debt Ratio of Erasca was 2024 -175.73 % . It decreases by -3.63% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Erasca Stock analysis

What does Erasca do? Erasca Inc., based in San Diego, US, is a clinical-stage precision oncology company focused on developing therapies for RAS/MAPK pathway-driven cancers. The company operates with a pipeline of 12 programs, including five clinical-stage candidates such as naporafenib, an ATP-competitive pan-RAF inhibitor, and seven discovery-stage initiatives targeting key oncogenic drivers. With 103 employees, Erasca is listed on the stock market since July 15, 2021. Erasca is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Erasca stock

Free Cash Flow to Debt Ratio of Erasca is -169.35 % in 2025.

Free Cash Flow to Debt Ratio of Erasca changed from -175.73 % to -169.35 %, representing a -3.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Erasca since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Erasca with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Erasca

All Key Metrics — Erasca